As the development of targeted radiopharmaceuticals and antibody-drug conjugates (ADCs) accelerates, Alfa Cytology has enhanced its radiopharmaceutical development service portfolio by integrating custom radiolabeling with physicochemical characterization services. This integration aims to provide comprehensive research support for biotechnology companies, pharmaceutical firms, and academic institutions.
Radiopharmaceuticals have become a cornerstone of precision medicine, with applications ranging from cancer diagnosis to targeted therapy. Increasingly, research projects employ radiolabeling technologies for pharmacokinetic studies, biodistribution analysis, and molecular imaging. The rapid progress of ADCs, peptide therapeutics, and targeted small molecules further drives demand for advanced radiopharmaceutical development capabilities.
However, successful radiolabeling alone is insufficient; critical attributes such as radiochemical purity, stability, lipophilicity, and target-binding capability require systematic evaluation. Alfa Cytology addresses this need by combining its custom radiolabeling for ADCs and targeted radiopharmaceuticals services with Radiopharmaceutical Physicochemical Characterization CRO services. This integrated approach covers key activities from radiolabeling to assessment of critical quality attributes, helping customers generate reliable data for candidate evaluation and subsequent studies, thereby improving development efficiency and reducing uncertainty.
In radiolabeling, the company supports antibodies, ADCs, peptide therapeutics, small molecules, and other targeted compounds, using a variety of radionuclides for diagnostic and therapeutic applications. These services apply to pharmacokinetic studies, biodistribution analysis, molecular imaging, and radiopharmaceutical development. Physicochemical characterization covers analysis of radiochemical purity, stability, lipophilicity (LogP/LogD), and immunoreactivity, enabling research teams to comprehensively evaluate candidate properties.
“The demand for high-quality radiolabeling and physicochemical characterization data continues to grow as radiopharmaceutical development advances,” said a spokesperson for Alfa Cytology. “By integrating our technical capabilities, we aim to provide customers with more efficient research support and help advance the development of innovative radiopharmaceuticals and targeted therapies.”
